A new common region of virus integration, Evi11, has been identified in two retrovirally induced murine myeloid leukemia cell lines, NFS107 and NFS78. By interspecific backcross analysis, it was shown that Evi11 is located at the distal end of mouse chromosome 4, in a region that shows homology with human 1p36. The genes encoding the peripheral cannabinoid receptor (Cnr2) and ␣-L-fucosidase (Fuca1) were identified near the integration site by using a novel exon trapping system. Cnr2 is suggested to be the target gene for viral interference in Evi11, since proviruses are integrated in the first intron of Cnr2 and retroviral integrations alter mRNA expression of Cnr2 in NFS107 and NFS78. In addition, proviral integrations were demonstrated within the 3 untranslated region of Cnr2 in five independent newly derived CasBrM-MuLV (mouse murine leukemia virus) tumors, CSL13, CSL14, CSL16, CSL27, and CSL97. The Cnr2 gene encodes a seven-transmembrane G-protein-coupled receptor which is normally expressed in hematopoietic tissues. Our data suggest that the peripheral cannabinoid receptor gene might be involved in leukemogenesis as a result of aberrant expression of Cnr2 due to retroviral integration in Evi11.
The identification of common virus integration sites (VISs) in retrovirally induced murine cancers has been proved successful for isolating transforming genes from hematopoietic malignancies and solid tumors (3, 30, 50) . Cellular genes may become aberrantly expressed following proviral integration, through activation by viral promoter or enhancer sequences. Alternatively, proviral integration within the protein-coding region of a gene may result in the expression of an altered product (50) . Abnormal expression of a proto-oncogene may provide the target cell with a growth abnormality and contribute to malignant transformation. A number of common VISs have been identified in murine retrovirally induced hematopoetic malignancies. These VISs are frequently designated ecotropic VISs (Evi1 to Evi10), although other names have been used as well (4, 9, 30, 31, 34, 37, 41) . Leukemia development in retrovirally induced leukemias is a multistep process which usually takes more then 3 months (3, 30, 50) . Thus, in a retrovirally induced leukemia, one can predict more than one common VIS, resulting in aberrant expression of multiple genes. The frequency of a particular common VIS is usually low, i.e., below 5%, indicating that several of different genes may be responsible for retrovirus-mediated leukemogenesis in mice (3, 30, 50) .
From a number of primary hematopoietic tumors, induced by Moloney murine leukemia virus (MoMuLV) or the wild mouse ecotropic retrovirus CasBrM-MuLV, in vitro cell lines have been established (3, 24) . In these interleukin-3 (IL-3)-dependent cell lines, several common VISs and potential oncogenes, including Evi1 (36) , Evi2 (9) , and His1 and His2 (4), have been found. In the present study, we describe the identification of a new common VIS, designated Evi11, in two myeloid leukemia cell lines and five newly isolated CasBrMMuLV-induced primary tumors.
Exon trapping has been used as an effective method for deducing mRNA-coding sequences from genomic DNA fragments (5, 10, 18, 23) . We used a new exon trap vector, pEVRF0-ET, based on the rabbit ␤-globin (R␤G) gene, which, in contrast to pSPL1 with an artificial intron (10) , contains the natural intervening sequence 2 of the R␤G gene (IVS2-␤). This exon trap system was applied to the Evi11 locus, and two genes, the peripheral cannabinoid receptor gene (Cnr2, formerly designated Cb2 [S2]) and the ␣-L-fucosidase gene (Fuca1), were identified. The results of the studies presented here suggest that the hematopoietic receptor gene Cnr2 is the candidate gene for viral interference in Evi11.
in liquid nitrogen. From these tumors, high-molecular-weight DNA was isolated (44) for Southern blot analysis.
Genomic cloning. From NFS107 cells, high-molecular-weight DNA was isolated as described previously (44) . The DNA was partially digested with Sau3A and separated on 0.4% agarose. DNA fragments of 9 to 23 kb were isolated by electroelution and purified on NACS columns (Bethesda Research Laboratories, Bethesda, Md.). These fragments were then ligated into BamHI EMBL3 phage arms and packaged (Stratagene, La Jolla, Calif.). DNA from 10 6 plaques was transferred to nitrocellulose filters and screened (44) (44) , and restriction maps of the different clones were prepared. DNA fragments adjacent to the VIS were isolated, subcloned in pBluescript II SKϩ (Stratagene), and used for Southern blot analysis using DNAs of the different DA and NFS cell lines. Cosmid clones were isolated from a female (4 to 8 weeks) mouse liver genomic library (Stratagene catalog no. 946305) and a murine embryonic stem cell genomic library in cosmid pTBE, using standard techniques (44) .
Southern and Northern blot analysis. Genomic DNA was isolated as described previously (16) , digested with the appropriate restriction enzymes, and electrophoresed on a 0.6% agarose gel. Fragments were transferred to Hybond-N ϩ (Amersham) nylon membranes with 0.25 M NaOH-1.5 M NaCl. Total RNA from cell lines was extracted with guanidinium isothiocyanate as described previously (44) . Ten micrograms of total RNA was separated on a 1% agarose-6% formaldehyde gel and blotted with 20ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate) onto Hybond-N ϩ nylon membranes (Amersham). Hybridization and washing procedures for Northern and Southern blots were identical to those described above. mRNA hybridization signals were quantitated by scanning of the Northern blots with a Vilber Lourmat camera and Bio-Profil V 4.6 software.
RNase protection. RNase protection was performed as described previously (44) . Fragments were cloned into pBluescript II SKϩ and linearized by using the proper enzymes, and RNA probes were synthesized by using T3 or T7 polymerase. For each incubation, 10 g of RNA and radiolabelled RNA probe (15,000 cpm) was suspended in 30 l of hybridization buffer [80% deionized formamide, 40 mM piperazine-N,NЈ-bis(2-ethanesulfonic acid) (PIPES; pH 6.4), 0.4 M sodium acetate, 1 mM EDTA]. The samples were heated to 85°C for 5 min and then incubated for 16 h at an annealing temperature of 50°C. To these mixtures, 300 l of RNase digestion buffer (10 mM Tris-HCl [pH 7.5], 5 mM EDTA, 200 mM sodium acetate) and 1 U of RNase One (Promega, Leiden, The Netherlands) were added. After 1 h at 37°C, the reaction was stopped by the addition of 3.3 l of 10% SDS and 20 g of carrier tRNA. The reaction products were precipitated with ethanol, fractionated by electrophoresis in a 6% polyacrylamide-7 M urea gel, and analyzed by autoradiography. A radiolabelled GAPDH RNA fragment was used as a control (28) .
Interspecific backcross mapping. Interspecific backcross progeny were generated by mating (C57BL/6J ϫ Mus spretus)F 1 females and C57BL/6J males as described previously (14) . A total of 205 backcross mice were used to map the 6.2 locus (see Results for details). DNA isolation, restriction enzyme digestion, agarose gel electrophoresis, Southern blot transfer, and hybridization were performed essentially as described elsewhere (29) . All blots were prepared with Hybond-N ϩ nylon membrane (Amersham). The probe, a 1.2-kb SalI/SstI fragment of mouse genomic DNA, was labelled with [␣-32 P]dCTP by using a random prime labelling kit (Amersham); washing was done to a final stringency of 0.8ϫ SSCP-0.1% SDS at 65°C. A 10.5-kb fragment was detected in HincII-digested C57BL/6J DNA, while 6.2-and 4.0-kb fragments were detected in M. spretus DNA. The presence or absence of the 6.2-and 4.0-kb M. spretus-specific HincII fragments, which cosegregated, were followed in backcross mice. The probes and restriction fragment length polymorphisms for the loci linked to the Evi11 locus, including the Gardner-Rasheed feline sarcoma viral oncogene homolog (Fgr) and natriuretic peptide precursor type A gene (Nppa), have been described previously (11) . Recombination distances were calculated as described by Green (22) , using the computer program SPRETUS MADNESS. Gene order was determined by minimizing the number of double and multiple recombination events across the chromosome.
Exon trapping. The exon trap vector was based on a eukaryotic expression vector pEVRF0, which had been designed for the analysis of mutant proteins (38) . The vector contains pSP65 bacterial plasmid sequences, the human cytomegalovirus enhancer/promoter, the translation initiation region from the herpes simplex virus thymidine kinase gene, splicing and polyadenylation signals from the R␤G gene, and the simian virus 40 origin of replication (46) (see Fig. 4A ). The R␤G fragment includes map position 905 (BamHI) to position 2080 of the R␤G gene. This fragment consists of IVS2-␤ flanked by thymidine kinase-R␤G exon 2 and R␤G exon 3. A 39-bp SmaI/HincII fragment from the polylinker of pBluescript II SKϩ was cloned into the HincII site of the IVS2-␤ to introduce multiple cloning sites. Genomic DNA from cosmids 5 and 10 (see Fig. 2A ) were partially digested with HpaII and separated on a 1% agarose gel, and fragments of between 2 and 5 kb were isolated. These HpaII fragments were ligated in the newly created ClaI site. COS cells were grown to Ϯ50% confluency. DEAEdextran (100 g/ml) and 10 g DNA in DMEM were added; after 2 h, this solution was replaced by 0.1 mM chloroquine in DMEM. Cells were incubated with this mixture for 3 h, and then the medium was refreshed by DMEM with 10% FCS. The cells were cultured for 2 to 3 days, and total RNA was isolated. Reverse transcriptase (RT)-PCR was carried out with primers 1A (5Ј-GGGGGATCTTGGTGGCGTG-3Ј) and 1B (5Ј-AGATCTCAGTGGTATT TGTGAGC3Ј). Subsequently, a nested PCR was performed with primers 2A (5Ј-CGTCTAGAGGAGTGAATTCTTTGC-3Ј) and 2B (5Ј-ATCCATGGAT CCTGAGAACTTCAG-3Ј). The PCR cycling conditions were as follows: for primers set 1A-1B, 1 min at 94°C, 1 min at 64°C, and 1 min at 72°C (30 cycles); for primer set 2A-2B, 1 min at 94°C, 1 min at 52°C, and 1 min at 72°C (30 cycles). Amplified fragments were visualized on a 2% agarose gel by ethidium bromide staining. Potential exons were subcloned into pBluescript II SKϩ by digestion with BamHI/EcoRI (see Fig. 4A ). Border sequences of R␤G exon 2 and R␤G exon 3 were thereby included in the cloned product.
Sequence analysis. Nucleotide sequencing was performed by the method of Sanger and Coulsen (45) . Fragments were cloned into pBluescript II SKϩ and sequenced with T3, T7, or sequence-specific primers. Deduced sequences were analyzed by using the BLAST network service of the National Center for Biotechnology Information.
RT-PCR. RT reactions were performed for 1.5 h at 37°C with 3 g of total RNA in 50 mM Tris-HCl (pH 8.3)-75 mM KCl-3 mM MgCl 2 -1 mM dithiothreitol-40 mM oligo(dT) 16 -0.5 mM deoxynucleoside triphosphates-1 U of RNAguard (Pharmacia)-100 U of SuperScript RT (Gibco, Breda, The Netherlands). The PCR mixture contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 150 M deoxynucleoside triphosphates, and 2.5 U of Taq polymerase. PCR cycling started with 10 min at 94°C and ended with a 10-min extension at 72°C.
cDNA cloning by PCR. All RT reactions for the RACE (rapid amplification of cDNA ends) experiments were done with 2 g of poly(A) ϩ RNA. Poly(A) ϩ RNA was purified by affinity chromatography using oligo(dT)-cellulose columns (Pharmacia). 3Ј RACE experiments were performed by using an oligo(dT) adapter primer [5Ј-GTCGCGAATTCGTCGACGCG(dT) 15 -3Ј] for first-strand synthesis. Subsequently, PCR was carried out with the adapter primer (5Ј-GTCGCGAATTCGTCGACGCG-3Ј) in combination with gene-specific primers (CBR15 [5Ј-CACGCTTAGTGATTTAGACT-3Ј; bp 2634 to 2653] and CBR16 [5Ј-GTATTTCAACATCAACTTGG-3Ј; bp 2654 to 2673]). Cycling parameters were 1 min at 94°C, 2 min at 57°C, and 3 min at 72°C (25 cycles). Products were cloned into pBluescript II SKϩ and sequenced. A 5Ј-Ampli-FINDER RACE kit (Clontech, Palo Alto, Calif.) was used to isolate additional 5Ј cDNA sequences. The strategy for the 5Ј RACE was as follows. A genespecific primer (CBR3 [5Ј-GTGAAGGTCATGGTCACACT-3Ј; bp 517 to 536]) was used for first-strand synthesis, and then an anchor primer was ligated to the cDNA 3Ј end. Subsequently, the anchor primer and nested primers (CBR9 [5Ј-CCGTTGGTCACTTCTGTCTC-3Ј; bp 199 to 218] and CBR10 [5Ј-GAGC TGTCCAGAAGACTGGG-3Ј; bp 138 to 158]) were used to amplify additional 5Ј cDNA fragments. Cycling parameters for both primer sets were 1 min at 94°C, 1 min at 57°C, and 3 min at 72°C (25 cycles). The products that were obtained by 5Ј RACE were cloned into pBluescript II SKϩ and sequenced. Nucleotide sequence accession number. The accession number for the murine Cnr2 sequence is X93168.
RESULTS

Identification of a common integration site (Evi11) in cell lines NFS107 and NFS78.
A Sau3A partial genomic library from NFS107 was prepared in EMBL3. The library was screened with a specific U 3 LTR probe from MoMuLV (15), and eight different LTR-positive clones were obtained (data not shown). The restriction map of one clone, 6.2, is shown in Fig. 1A . From this phage clone, a nonviral, nonrepetitive 1.2-kb SstI/SalI probe F (Fig. 1A ) was isolated and used for further analysis. With this probe, DNAs from 13 MoMuLVand 9 CasBrM-MuLV-induced leukemic cell lines were screened by Southern analysis using the restriction enzymes PvuII, SstI, XbaI, KpnI, PstI, and HindIII. As shown in Fig. 1B , rearrangements were identified in NFS107 and in the leukemic cell line NFS78. Southern analysis also revealed that NFS78 had lost its normal allele (Fig. 1B , SstI, KpnI, PstI, and HindIII). NFS107 and NFS78 are both IL-3 dependent and do not respond to granulocyte and granulocyte-macrophage colony-stimulatory factors (G-CSF and GM-CSF), stem cell factor, and IL-7 (data not shown). NFS107 cells express the my-
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Evi11, A NOVEL COMMON VIRUS INTEGRATION SITEeloid markers myeloperoxidase, Mac-1, and Mac-2 (27) . NFS78 is a leukemic cell line with myeloblastic characteristics (24) and expresses the myeloid marker Mac-1 (27) . Immunoglobulin heavy-chain genes of both cell lines are in germ line configuration. Southern blotting and genetic backcross analysis with a fragment derived from another integration site in NFS107 demonstrated that this integration had occurred in the recently identified common VIS, Evi3 (data not shown and reference 31). NFS78 expresses another common VIS, Evi1 (36) . NFS22 (Fig. 1B ) and 19 other cell lines did not show rearrangements in the Evi11 locus after hybridization with probe E, F, or C (Fig. 2B) . To obtain genomic DNA of the normal Evi11 locus, two genomic cosmid libraries were screened with probe F (Fig. 1A and 2B ). We isolated three cosmid clones, 32B, 5, and 10, covering a region of approximately 70 kb of the locus that we designated Evi11. A limited restriction map of Evi11 is shown in Fig. 2A . The orientation of the viral DNA in NFS107 and NFS78 was deduced from restriction enzyme analysis of the normal genomic organization (cosmids 5 and 32B) and Fig. 1B , in combination with the restriction map of CasBrM-MuLV (accession no. X57540). In NFS78, retroviral DNA is oriented opposite the integrated viral DNA within the same locus in NFS107 (Fig. 2A) . The distance between the two integrations is approximately 3 kb. Chromosomal localization of Evi11. The chromosomal localization of Evi11 was initially determined to be on murine chromosome 4 by fluorescence in situ hybridization (FISH) analysis (data not shown). A more exact positioning of Evi11 was obtained by interspecific backcross analysis using progeny derived from matings of [(C57BL/6J ϫ M. spretus)F 1 ϫ C57BL/6J] mice. This interspecific backcross mapping panel has been typed for over 2,100 loci that are well distributed among all mouse autosomes and the X chromosome (14, 14a) . C57BL/6J and M. spretus DNAs were digested with several restriction enzymes and analyzed by Southern blot hybridization for informative restriction fragment length polymorphisms, using the mouse 1.2-kb SstI/SalI probe F (Fig. 1A) . Cosegregating 6.2-and 4.0-kb M. spretus-specific HincII fragments were used to monitor the segregation of the Evi11 locus in backcross DNAs. The mapping results indicated that Evi11 is located in the distal region of mouse chromosome 4 (Fig. 3) . Although 117 mice were analyzed for all three markers shown in the haplotype analysis (Fig. 3) , up to 121 mice could be typed for one pair of markers. Each locus was analyzed in pairwise combinations for recombination frequencies, using (Fig. 3) .
Identification of transcribed sequences in the Evi11 locus by using exon trapping. To isolate coding sequences from the Evi11 locus, an exon trapping system was designed (Fig. 4A ) and applied to cosmid clones 5 and 10 ( Fig. 2A) . Partially HpaII-digested fragments of cosmids 5 and 10, between 2 and 5 kb, were cloned into the ClaI site of the exon trap vector. These constructs were pooled in groups of six clones per COS cell transfection. Thirty transfections were performed. RT-PCR was carried out on RNA isolated from the transfected COS cells. Potential exons with sizes ranging from 50 to 300 bp were amplified from the different pools, using primer set 1A-1B followed by 2A-2B, and visualized by ethidium bromide staining. Eight examples of COS cell transfections are shown in Fig. 4B (lanes 1 to 8) . Transfection of the exon trap vector without insert resulted in the isolation of a 97-bp fragment representing the fusion of exons 2 and 3 of the R␤G gene (Fig.  4B, lane V) . Potential exons were subcloned into BamHI/ EcoRI-digested (Fig. 4A) pBluescript II SKϩ and sequenced. The DNA sequences were compared to those in the National Center for Biotechnology Information database. Among 16 clones analyzed, one exon was the mouse homolog of exon 3 of human FUCA1 (32), a gene which by interspecific backcrossing had been shown to be located near Evi11 (Fig. 3) . Seven clones contained sequences that were homologous to part of the coding region of human CNR2 (39) . However, the Cnr2 fragments were trapped between the two R␤G exons in the reversed transcriptional orientation. Sequence analysis of these trapped fragments and of the human cDNA of CNR2 demonstrated the presence of cryptic splice sites at the proper positions in the reversed orientation (see Fig. 6A ). Eight clones contained cosmid vector sequences. The trapped fragments were radiolabelled and used for Northern analysis to examine the expression of the representing genes in the different cell lines. Two different mRNAs, of Ϯ1.6 and Ϯ4.0 kb, were identified (Fig.  5) . Analysis using separate probes revealed that the Ϯ1.6-kb signal represented ␣-L-fucosidase, and the Cnr2 fragment detected the Ϯ4.0-kb mRNA. In NFS78, NFS107, and control cell lines NFS22 and NFS36, variable levels of Cnr2 mRNA were apparent (Fig. 5) . In NFS78, Cnr2 mRNA levels were higher than in control cell lines, whereas in NFS107, no Cnr2 mRNA could be identified (Fig. 5 and Table 1 ). In fact, Northern analysis using RNAs from a panel of cell lines demonstrated variable levels of Cnr2 mRNA expression in all DA and NFS lines (data not shown). Levels of Fuca1 transcripts in the different cell lines were comparable (Fig. 5, Table 1 , and data not shown). Although the levels of Fuca1 mRNA in the different leukemic cell lines (Table 1 and data not shown) were less variable than the Cnr2 mRNA levels, the Northern analysis was not conclusive with respect to altered gene expression caused by virus integration.
The Cnr2 nucleotide sequence and exon structure. Southern blot analysis was carried out on the three Evi11 cosmid clones 
Evi11, A NOVEL COMMON VIRUS INTEGRATION SITEto determine the positions of the amplified fragments ( Fig.  2A) . The trapped Cnr2 fragment was mapped on a 3-kb EcoRI/ EcoRI fragment (Fig. 2) . The localization was confirmed by the presence of a relatively rare SalI site in this fragment. ␣-LFucosidase exon 3 is situated approximately 12 kb from the provirus in NFS78. Since Cnr2 is located nearer the VIS than the ␣-L-fucosidase gene, and the gene encodes a hematopoietic receptor (39) , which may be involved in monocyte/macrophage differentiation (40), we decided to determine the nucleotide sequence and genomic structure of Cnr2. Southern analysis with 5Ј and 3Ј cDNA probes of the human CNR2 gene suggested that the entire protein-coding sequence was located within the 3-kb EcoRI/EcoRI fragment (Fig. 2) . HpaII and Sau3A fragments of the 3-kb EcoRI/EcoRI fragment were subcloned into, respectively, the ClaI and BamHI sites of pBluescript II SKϩ and sequenced (Fig. 6A) . The merged nucleotide sequences of the 3-kb EcoRI/EcoRI fragment showed that the complete protein-coding sequence of the murine Cnr2 receptor is present within this 3-kb fragment. The amino acid sequence of the murine Cnr2 gene product is 82% homologous to that of the human CNR2 gene product. The C-terminal end of the murine homolog lacks nine amino acids. An amino acid sequence comparison of murine Cnr2, human CNR2 (39), and murine (accession no. U22948) and human (CNR1 [21] ) brain cannabinoid receptor 1 gene products is shown in Fig. 6B . Nucleotide sequencing of the Cnr2 proteincoding region from NFS107 and NFS78 cDNA did not show any mutations. The 3Ј noncoding sequence was isolated by 3Ј RACE on poly(A) ϩ from control cell line NFS22 by using two gene-specific primers (CBR15 and CBR16). Two fragments, which terminated at bp 2951 and 3756, were isolated. The 3Ј untranslated regions (UTRs) appeared to be, respectively, 1,724 and 2,528 bp long, with putative polyadenylation signals (AAUAAA) at bp 2928 and 3743. This variability in 3Ј UTR lengths has also been shown for the rat brain cannabinoid receptor (35) . The Cnr2 sequence identified so far is located in one exon. Upstream of the ATG start site of mouse Cnr2 on the 3-kb EcoRI/EcoRI fragment, a potential 3Ј splice acceptor site was identified (Fig. 7A) . To investigate whether 5Ј exons, which could splice to this potential acceptor site, existed, 5Ј RACE was carried out using poly(A) ϩ RNA from the control cell line NFS22. Amplification with the anchor primer and CBR9, followed by a nested PCR with the anchor primer and CBR10, resulted in the isolation of a fragment of 179 bp (Fig.  6A ). This fragment was cloned into pBluescript II SKϩ, and sequence analysis revealed that an exon of at least 121 bp was spliced to the predicted splice acceptor site. Since this exon introduces a stop codon in frame with the ATG start site, this exon is noncoding (Fig. 6A) . Interestingly, Southern blot anal- (Fig. 5) .
ysis demonstrated that exon 1 of Cnr2 is located approximately 20 kb upstream of protein-coding exon 2. Thus, virus integrations in NFS107 and NFS78 have occurred in an intron of Cnr2 (Fig. 7A ). Cnr2 expression in leukemic cell lines. Northern analysis demonstrated variable levels of Cnr2 mRNA expression in the distinct cell lines studied (Fig. 5, Table 1 , and data not shown) but was not conclusive with respect to the viral integrations. Since in NFS78 and NFS107, proviral DNA is integrated in the Cnr2 intron, we verified with RNase protection whether the levels of expression of the two exons had been altered. A 195-bp EcoRI (anchor 5Ј RACE)/NcoI fragment overlapping Cnr2 exons 1 and 2 ( Fig. 7A ) was generated to protect both exons with RNase protection. RNase protection analysis revealed variable levels of full-length Cnr2 mRNA in the control cell lines (NFS36, NFS56, NFS58, NFS61, and NFS124) (Fig. 7B, 187 bp [exon 1 ϩ 2] ). In NFS107, fulllength Cnr2 as well as 137-bp transcripts, representing exon 1, were detected. Thus, although no Cnr2 transcripts could be detected in NFS107 by Northern blot analysis, Cnr2 mRNA was demonstrated by using the more sensitive RNase protection technique. In NFS78, full-length Cnr2 mRNA could not be demonstrated; however, a 50-bp fragment which corresponds to exon 2 mRNA was protected. This finding is in agreement with the Southern blot analysis (Fig. 1B) , showing a normal and rearranged allele in NFS107 and only an abnormal allele in NFS78. 5Ј RACE carried out on poly(A) ϩ RNA of NFS78 resulted in fragments of different sizes. Sequencing (Fig. 6A) showed that in this cell line, another noncoding exon located downstream of provirus DNA was fused to the splice acceptor site of exon 2 of Cnr2 (Fig. 7A) . In an assay using a 680-bp probe specific for exons 1Ј and 2 (Fig. 7A) , two large fragments (600 and 430 bp) were protected in NFS78 only (Fig. 7C) . The 600-bp band represents the complete exon 1Ј-plus-2 transcript, whereas the smaller band corresponds with a part of exon 1Ј fused to exon 2. In the other cell lines, a band of 350 bp which represents exon 2 only is protected. Thus, the RNase protection analysis demonstrate altered aberrant Cnr2 mRNA expression in both NFS107 and NFS78.
Evi11 in CasBrM-MuLV-induced primary tumors. To determine the frequency of Evi11/Cnr2 retroviral insertions, Southern blot analysis was carried out with probe E, F, or C (Fig. 2B ) and different restriction enzymes on high-molecularweight DNA isolated from CasBrM-MuLV-induced splenic tumors. Interestingly, DNA rearrangements were observed within the Evi11 locus in five cases, i.e., CSL13, CSL14, CSL16, CSL27, and CSL97, using probe C (Fig. 8) , which corresponds to the protein-coding region of Cnr2 (Fig. 2B) . No rearrangements were detected in control primary tumors, e.g., CSL103 and CSL12. From the Southern blot analysis of DNA digested with multiple enzymes (SstI, PstI, and BamHI), it was concluded that retroviral integrations in Evi11 had occurred within the 3Ј UTR of Cnr2 in the same transcriptional orientation (Fig. 2B) . The locations and orientations of the proviruses were confirmed by PCR analysis using Cnr2-and MuLV LTRspecific primers (data not shown). 
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DISCUSSION
Neoplasias induced by retroviruses that lack dominant-acting oncogenes have been shown to depend on proviral integrations into particular loci of the cellular genome (3, 30, 50) . Integration of viral DNA independently in the same locus in different tumors might indicate loci that have a functional role in the multistep process of malignant transformation. In two murine IL-3-dependent myeloid leukemia cell lines (24) , i.e., NFS107 and NFS78, and five primary tumors, i.e., CSL13, CSL14, CSL16, CSL27, and CSL97, induced in CasBrMMuLV-infected NFS/N mice, a new common virus integration site, Evi11, was identified and cloned. NFS107 was initially chosen for this study because of the absence of rearrangements in loci of several known proto-oncogenes (27) . Interestingly, however, among eight integration sites that we isolated from NFS107, one represented the recently identified common VIS Evi3 (data not shown and reference 31). This finding might suggest that alterations in the expression of the Evi11 and an Evi3 proto-oncogene synergize to generate a malignantly transformed myeloid cell. Likewise, in NFS78 leukemia cells, provirus is integrated in the Evi1 locus (36) , which may suggest that aberrant expression of an Evi11 proto-oncogene and Evi1 cooperated in the development of the latter myeloid leukemia. Cooperation of genes involved in the initiation and/or progression of hematopoietic tumors has been shown by others (30, 41) .
To isolate genes located near the VIS, we established an exon trapping/amplification system based on the expression vector pEVRF0 (38) . This exon trap vector is related to the pSPL1-vector (10), which also uses the R␤G gene exons 2 and 3. The main difference between pEVRF0 and pSPL1 is that the natural intervening sequence, IVS2-␤, is used in pERVF0, whereas in pSPL1, IVS2-␤ is replaced by the human immunodeficiency virus tat intron. Thus, by using pERVF0, we wished to avoid the possibility of isolating false positives caused by a cryptic splice site present within the tat intron sequence (13, 42) . With the novel exon trapping system, we identified two genes in Evi11. The ␣-L-fucosidase exon that was trapped is the mouse homolog of exon 3 of human FUCA1 (20) . The second fragment that was isolated from the Evi11 locus encodes part of the murine cannabinoid receptor 2, based on a strong homology to human CNR2 (39) and identity to the recently cloned mouse Cnr2 (48) . The isolated fragment of Cnr2 was trapped in the incorrect transcriptional orientation because of the presence of cryptic 5Ј and 3Ј splice sites on the noncoding strand (Fig. 6A) . Thus, although apparently exons can be isolated efficiently by using pERVF0, it is also clear that false positives may be isolated by using exon trapping procedures. Since sequences derived from the cosmid vector were also trapped, it appears useful to eliminate vector DNA before cloning genomic DNA into the pERVF0 vector.
Two genes, Fuca1 and Cnr2, were identified in the Evi11 locus. The data suggest that Cnr2 is the candidate target gene, since provirus is integrated in the Cnr2 intron in NFS78 and NFS107, and although the mechanism needs further study, virus integrations in this locus lead to aberrant Cnr2 mRNA expression in NFS78 and NFS107. In addition, all proviral integrations identified in the CasBrM-MuLV-induced primary (Fig. 2B) on PstI and SstI-digested genomic DNA from CasBrM-MuLV-induced primary tumors. The locations and orientations of the retroviruses in Evi11 are depicted in Fig. 2B. tumors reside within the 3Ј UTR of Cnr2. These integrations resemble classical proviral integrations which generally enhance expression of the target gene (3, 30, 50) . However, the possibility remains that another gene within the Evi11 locus is affected due to retroviral insertion.
Cnr2 encodes a hematopoietic receptor that belongs to the class of seven-transmembrane G-protein-coupled receptors. Cnr2 consists of a small 5Ј noncoding exon 1 and a large exon 2 that contains the complete protein-coding region. Interestingly, small 5Ј noncoding exons have been identified in a series of genes that encode G-protein-coupled receptors, e.g., the Burkitt's lymphoma receptor 1 gene (BLR1) (17) , the mas oncogene-related rat thoracic aorta receptor gene (RTA) (43) , and recently also CNR1 (47) . This could suggest that the small 5Ј exons are important in regulation of gene expression. In NFS78 and NFS107 cells, proviruses are integrated in the intron that separates exon 1 from exon 2. Our data indicate abnormal expression of Cnr2 exon 1 in NFS107 and NFS78. The RNase protection data are indicative of an mRNA in NFS107 that contains exon 1 only. This deleted transcript is probably the result of the polyadenylation signal introduced by the LTR of the provirus that is integrated in the proper orientation downstream of exon 1 (Fig. 7A) . In NFS78, exon 1 is absent and an alternative exon is fused to the protein-coding exon 2 ( Fig. 6A and 7A ). If aberrant mRNA expression of exon 1 as the result of proviral integration leads to abnormal levels of Cnr2 receptors and contributes to leukemic transformation, this would suggest that exon 1 contains important regulatory sequences. We are currently raising antibodies to examine the levels of Cnr2 receptors in NFS78, NFS107, and control cell lines.
Interestingly, RNase protection experiments have demonstrated that Cnr2 may be expressed in most hematopoietic lineages and that the ligand for cannabinoid receptors, anandamide, synergistically stimulates proliferation of hematopoietic progenitor cell lines with cytokines, e.g. IL-3, GM-CSF, erythropoietin, and G-CSF (52) . Thus, Cnr2 appears to encode an important hematopoietic receptor which following activation enhances the response to hematopoietic growth factors. This finding adds further support to the hypothesis that this receptor, when aberrantly expressed, may alter the proliferative response of hematopoietic cells and contribute to the development of leukemia. Several other genes that encode G-protein-coupled receptors have been implicated in oncogenic transformation (1, 49, 53, 54) .
FISH analysis and interspecific backcrossing demonstrated that Evi11 is located on the distal end of murine chromosome 4. This locus is distinct from known proto-oncogenes and common viral integration loci previously identified in the mouse. This particular region on murine chromosome 4 is homologous to a region on human chromosome 1p, i.e., 1p36. Evi11 was found to localize between two genes, Fgr and Nppa. These comparative mapping results suggest that FUCA1 and CNR2 map to human 1p36 as well. In fact, it had already been shown that human FUCA1 resides on chromosome 1p36 (20) . FISH analysis using a human CNR2 cDNA probe indeed demonstrated that this gene is also located on 1p36 in humans (data not shown). 1p36 is involved in breakpoints in certain cases of acute myeloid leukemia and myelodysplastic syndrome (7, 51) but also in other malignancies, e.g., neuroblastomas (6, 12, 33) . This finding raises the question as to whether the human Evi11 locus and possibly CNR2 are mutated and aberrantly expressed in certain human diseases with 1p36 abnormalities.
